
New COVID Variant Stratus: Symptoms, Duration & What to Know
You’ve probably seen headlines about a new COVID variant called Stratus. It’s spreading fast, but the good news is that it doesn’t appear to cause more severe illness than earlier versions.
First detected: January 2025 in Southeast Asia ·
Spread to US states by June 2025: 38 states ·
Dominant variant as of September 2025: XFG (Stratus) and NB.1.8.1 (Nimbus) ·
Reported symptoms count: 8 common symptoms
Quick snapshot
- Stratus is a nickname for the XFG variant, first detected in January 2025 in Southeast Asia (Stony Brook Medicine)
- No evidence of more severe disease compared to previous Omicron subvariants (Ohio State University Health)
- Long-term immunity after a Stratus infection remains uncertain — ongoing studies have not yet produced definitive data (NewYork-Presbyterian)
- Exact transmissibility advantage over other circulating variants is still being studied (NewYork-Presbyterian)
- First detected: January 2025 in Southeast Asia (Stony Brook Medicine)
- Dominant in the US by September 2025 at 79% of cases (NewYork-Presbyterian)
- WHO continues to monitor XFG under its “variants under monitoring” list (UNMC)
- Health agencies recommend updated vaccines targeting current JN.1 lineages (UKHSA Blog)
Five key facts about Stratus reveal a pattern: high transmissibility, familiar symptoms, and no spike in severity.
| Attribute | Detail |
|---|---|
| Variant official name | XFG |
| Common name | Stratus |
| First detected | January 2025, Southeast Asia |
| US dominance | June 2025 |
| Severity | Not more severe than previous Omicron variants |
The implication: Stratus is notable for its spread speed, but not for any alarming change in what the virus does to the body.
What is the new COVID stratus?
Stratus is the informal name for the XFG variant, a descendant of the Omicron lineage that was first detected in January 2025 in Southeast Asia (Stony Brook Medicine). By June 2025, it had been detected in 38 US states and was designated a “variant under monitoring” by the World Health Organization (UNMC).
What is XFG?
- XFG is the official lineage name for the variant widely referred to as Stratus
- It belongs to the Omicron family, carrying mutations that enhance transmissibility without causing more severe outcomes (Ohio State University Health)
- The World Health Organization tracks it alongside NB.1.8.1 (Nimbus) as part of ongoing global surveillance (UNMC)
How does Stratus differ from previous variants?
- Stratus shows “marginal additional immune evasion” compared to Nimbus, meaning it can partially dodge existing antibodies (Stony Brook Medicine)
- Symptom profile is nearly identical to earlier Omicron subvariants — no new or unusual presentations have been reported (Ohio State University Health)
- Hospitalization rates have not seen a dramatic increase compared to prior waves (NewYork-Presbyterian)
How widespread is it?
- By late summer 2025, Stratus accounted for approximately 70% of US COVID cases (Prevention Magazine)
- In the week ending September 6, 2025, Stratus (XFG) made up 79% of US cases, surpassing Nimbus (NewYork-Presbyterian)
- By September 2025, both XFG and NB.1.8.1 were reported as dominant variants in the US and UK (UKHSA Blog)
The pattern: Stratus gained dominance through transmission speed, not through causing worse illness — and that changes how you should think about risk.
What are the symptoms of Stratus COVID?
Symptoms of Stratus align closely with what we’ve seen from other Omicron variants. The most commonly reported symptoms include a painful cough, congestion, sore throat, hoarseness, fatigue, headache, and fever or chills (Ohio State University Health). Sore throat is especially prominent, according to infectious disease experts at NewYork-Presbyterian.
Common symptoms list
- Persistent dry cough
- Nasal congestion or runny nose
- Sore throat and hoarseness
- Fatigue and muscle aches
- Headache
- Fever or chills
- Shortness of breath (less common but reported)
Are symptoms different from earlier variants?
- No new symptoms have been documented with Stratus — the presentation matches previous Omicron subvariants (iHealth Labs)
- Loss of taste or smell still occurs but is less commonly reported than in early pandemic strains
- Symptom severity appears comparable to prior variants, with no evidence of increased respiratory distress (Ohio State University Health)
Patients dealing with Stratus should expect familiar COVID symptoms, not a new set of surprises. The sore throat may be the most noticeable clue.
How long does the new strain of COVID last?
Most people infected with Stratus recover within 5 to 10 days, according to Ohio State University Health. The duration mirrors what we saw with earlier Omicron subvariants, though some individuals may experience lingering fatigue or cough beyond the typical window.
Typical duration of illness
- Acute symptoms generally resolve within 7 days, with full recovery inside 10 days for most cases (Ohio State University Health)
- Sore throat and cough tend to peak in the first 2-3 days
- Fatigue can persist for 1-2 weeks in some individuals, though this is not unique to Stratus
Factors affecting recovery time
- Age and underlying health conditions play a significant role in recovery speed
- Vaccination status: those who are up to date on COVID vaccines tend to recover faster (NewYork-Presbyterian)
- Access to antiviral treatment (Paxlovid, remdesivir) can shorten illness duration in high-risk individuals
The catch: recovery time is predictable for most, but the subset of patients with prolonged symptoms means “long COVID” remains a real possibility worth planning for.
How can I tell if I have COVID or a cold?
Differentiating Stratus from a common cold is tricky because many symptoms overlap. Both can cause runny nose, sore throat, and cough. However, COVID tends to bring fever, body aches, and sometimes loss of taste or smell — symptoms rarely seen with a standard cold (Ohio State University Health).
Differences in symptoms
- COVID: fever or chills, headache, muscle aches, fatigue, possible loss of taste or smell
- Cold: predominantly runny nose, sneezing, mild sore throat, rarely fever
- Stratus’s sore throat can be intense, but this alone doesn’t distinguish it from a cold (NewYork-Presbyterian)
Testing to confirm
- Only a PCR or rapid antigen test can definitively tell COVID from a cold (Stony Brook Medicine)
- Home tests still detect Stratus because it belongs to the Omicron lineage
- If symptoms are mild and you test negative, a cold is the more likely culprit
When fever, body aches, or loss of smell are present alongside a sore throat, assume COVID until a test says otherwise. Cold symptoms alone — runny nose, sneezing — lean away from COVID.
The trade-off: relying on symptom guessing wastes time — a 15-minute antigen test gives certainty that symptom checklists cannot.
Is COVID going around now in 2026?
Yes, COVID continues to circulate in 2026 with seasonal waves. As of late 2025, Stratus (XFG) and Nimbus (NB.1.8.1) were the most common variants driving cases in the US and UK (UKHSA Blog). The virus hasn’t gone away — it’s become a recurring seasonal threat.
Current circulation of COVID-19 variants
- Stratus (XFG) dominated US cases at 79% in early September 2025 (NewYork-Presbyterian)
- Nimbus (NB.1.8.1) remains a co-circulating variant, especially in parts of Europe
- WHO’s “variants under monitoring” list continues to track both as of June 2025 (UNMC)
Stratus and Nimbus dominance
- By September 2025, both XFG (Stratus) and NB.1.8.1 (Nimbus) were established as dominant in the US and UK (UKHSA Blog)
- Neither variant leads to more severe illness than previous Omicron variants (Ohio State University Health)
- Winter surges remain a possibility as immunity wanes and indoor gatherings increase
COVID is now a seasonal virus. Expect waves of Stratus and similar variants every winter and summer. The risk of severe disease remains low for vaccinated, healthy individuals but persists for older adults and the immunocompromised.
The implication: treating COVID as a seasonal reality rather than a crisis lets you plan — boosters, tests, and masks in high-risk settings remain sensible tools.
Two variants, one key difference: Stratus spreads faster, but the symptom profiles and severity are nearly identical.
| Feature | Stratus (XFG) | Nimbus (NB.1.8.1) |
|---|---|---|
| Lineage | XFG, Omicron descendant | NB.1.8.1, Omicron descendant |
| First detected | January 2025, Southeast Asia | Late 2024, Europe |
| Immune evasion | Marginal additional evasion over Nimbus (Stony Brook Medicine) | Moderate immune evasion, baseline for current vaccines |
| Symptoms | Cough, sore throat, fever, fatigue, headache | Same: cough, sore throat, fever, fatigue, headache |
| Severity | Not more severe than prior Omicron (Ohio State University Health) | Not more severe than prior Omicron |
| US prevalence (Sep 2025) | 79% of cases (NewYork-Presbyterian) | Declining from peak |
The pattern: both are Omicron subvariants that behave almost identically — Stratus just won the transmission race.
Timeline of the Stratus variant
The spread of Stratus from a regionally detected variant to global dominance took less than a year. Key milestones:
- January 2025: First detection of XFG (Stratus) in Southeast Asia (Stony Brook Medicine)
- June 2025: Spread to 38 US states; WHO designates it a “variant under monitoring” (UNMC)
- September 2025: XFG and NB.1.8.1 (Nimbus) become dominant variants in the US and UK (UKHSA Blog)
The pattern: each new variant’s timeline is compressing, but the public health response has kept pace — monitoring, vaccines, and treatments remain effective.
What we know — and what’s still uncertain
Research confidence around Stratus is moderate: the symptom profile, transmission timeline, and severity are well-documented, but some questions remain open.
Confirmed facts
- Symptoms match previous Omicron variants — no new presentations (Ohio State University Health)
- No evidence of increased hospitalization or death rates (NewYork-Presbyterian)
- XFG is highly transmissible, accounting for 79% of US cases by September 2025 (NewYork-Presbyterian)
What’s still unclear
- Long-term immunity after infection with Stratus is not yet fully understood
- Exact transmissibility advantage over other circulating variants remains under study
- Effectiveness of current vaccines against infection (though they remain protective against severe disease) (UKHSA Blog)
Confirmed facts strongly outweigh unknowns for Stratus. The core message — familiar symptoms, no new severity — is backed by multiple tier-1 and tier-2 sources. The uncertainties are about the edges, not the center.
The implication: the evidence base is solid enough to guide decisions, even while researchers continue to fill in the remaining gaps.
Expert perspectives
“It’s not causing more severe disease or more deaths than what we’ve seen with other variants.”
— Ohio State University Health, infectious disease team
“The same reliable prevention strategies — vaccination, masking in crowded indoor settings, staying home when you are sick — remain our best defenses.”
— NewYork-Presbyterian, infectious disease expert
“Current COVID-19 variants do not lead to more severe illness overall.”
— UKHSA Blog, government public health agency
“The most common symptom right now appears to be a sore throat that’s quite painful.”
— NewYork-Presbyterian, clinical observation
The Stratus variant is a reminder that COVID hasn’t become irrelevant — but it has become manageable. For the vaccinated individual, the choice is clear: test when symptoms include fever or body aches, rest during the 5-10 day window, and remember that severity hasn’t escalated. For public health agencies, the pattern is equally clear: keep monitoring, update vaccines, and communicate calmly. Stratus isn’t the start of something new — it’s the continuation of a virus we’ve learned to live with, and the data says we can.
For a broader overview of how the new Stratus variant is affecting different regions, the new Stratus variant offers detailed data on symptoms and vaccine effectiveness.
Frequently asked questions
Can you get Stratus COVID more than once?
Yes, reinfection with Stratus is possible, especially as immunity from prior infection or vaccination wanes over time. However, each subsequent infection tends to be milder for most people.
Does the COVID vaccine protect against the Stratus variant?
Vaccines remain effective at preventing severe disease, hospitalization, and death from Stratus. Protection against infection may be reduced due to the variant’s immune evasion, but the updated 2024-2025 vaccines targeting JN.1 lineages provide broader coverage (UKHSA Blog).
Is Stratus more contagious than the Omicron variant?
Stratus is roughly as contagious as earlier Omicron subvariants. Its rapid rise to dominance (79% of US cases by September 2025) is attributed more to “marginal additional immune evasion” than a massive leap in transmissibility (Stony Brook Medicine).
What should I do if I think I have Stratus?
Test using a home antigen test or visit a testing site. If positive, isolate according to current CDC guidance (typically 5 days after symptom onset). Contact your doctor if you are at high risk for severe illness — antivirals like Paxlovid may be appropriate.
Are there specific treatments for the Stratus variant?
No variant-specific treatments exist. Standard COVID-19 treatments — antivirals (Paxlovid, remdesivir), supportive care, and symptom management — remain effective (Stony Brook Medicine).
Does Stratus cause loss of taste or smell?
Loss of taste or smell is less common with Stratus than with earlier COVID strains like Delta, but still reported in some cases. It is not a hallmark symptom of this variant. Sore throat and cough are more frequent presentations.
How long after exposure do symptoms appear?
The incubation period for Stratus is estimated at 2-5 days, similar to other Omicron subvariants. Symptoms may appear as early as 24 hours after exposure in some individuals.
Should I get tested if I have mild symptoms?
Yes, even mild symptoms warrant a test to confirm COVID, protect vulnerable contacts, and determine if you need treatment. Home antigen tests are effective at detecting Stratus.